Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
32.44
+0.45 (1.41%)
At close: Feb 10, 2026, 4:00 PM EST
32.38
-0.06 (-0.18%)
After-hours: Feb 10, 2026, 7:59 PM EST
Stoke Therapeutics Employees
Stoke Therapeutics had 128 employees as of December 31, 2024. The number of employees increased by 18 or 16.36% compared to the previous year.
Employees
128
Change (1Y)
18
Growth (1Y)
16.36%
Revenue / Employee
$1,606,500
Profits / Employee
$316,930
Market Cap
1.85B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 128 | 18 | 16.36% |
| Dec 31, 2023 | 110 | -7 | -5.98% |
| Dec 31, 2022 | 117 | 15 | 14.71% |
| Dec 31, 2021 | 102 | 23 | 29.11% |
| Dec 31, 2020 | 79 | 23 | 41.07% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 1,372 |
| MannKind | 407 |
| Ardelyx | 395 |
| Vericel | 357 |
| Nurix Therapeutics | 317 |
| Nuvation Bio | 291 |
| Syndax Pharmaceuticals | 270 |
| Aurinia Pharmaceuticals | 130 |
STOK News
- 6 days ago - Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Business Wire
- 14 days ago - Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA - PRNewsWire
- 25 days ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 26 days ago - Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity - Seeking Alpha
- 4 weeks ago - Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome - Business Wire
- 5 weeks ago - Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting - Business Wire
- 2 months ago - Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting - Business Wire